Currently, only seven drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD: three cholinesterase inhibitors (donepezil, rivastigmine, galantamine); a glutamate regulator (memantine); a combination of a cholinesterase inhibitor and glutamate regulator (donepezil/memantine); and two amyloid β-directed monoclonal antibodies (aducanumab and lecanemab) (Medications for Memory Loss, 2022). Here, BCHE is linked to memory impairment.